Ardsley Advisory Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Ardsley Advisory Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.8M	Sell	465,000 -90,000	-16%	-$3M	1.64%	14
2026 Q1	$16.7M	Sell	555,000 -25,000	-4%	-$804K	2.13%	10
2025 Q4	$18.1M	Buy	580,000 +80,000	+16%	+$1.97M	1.99%	9
2025 Q3	$10.1M	Buy	500,000 +100,000	+25%	+$1.76M	1.25%	24
2025 Q2	$6.7M	Sell	400,000 -100,000	-20%	-$1.61M	0.88%	40
2025 Q1	$7.68M	Buy	500,000 +200,000	+67%	+$3.57M	1.47%	17
2024 Q4	$6.61M	Sell	300,000 -52,900	-15%	-$962K	1.05%	30
2024 Q3	$6.36M	Buy	352,900 +102,150	+41%	+$1.79M	1.05%	40
2024 Q2	$4.07M	Buy	+250,750	New	+$3.86M	0.6%	55
2017 Q2	–	Sell	-15,000	Closed	-$464K	–	173
2017 Q1	$481K	Buy	+15,000	New	+$512K	0.07%	103
2016 Q2	–	Sell	-5,000	Closed	-$268K	–	196
2016 Q1	$268K	Sell	5,000 -85,000	-94%	-$4.99M	0.04%	109
2015 Q4	$5.91M	Buy	+90,000	New	+$5.56M	0.77%	42

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Ardsley Advisory Partners's TEVA Position: Q2 2026 in Review

Ardsley Advisory Partners reduced its Teva Pharmaceuticals (TEVA) stake by 16% in Q2 2026, selling an estimated $3M and leaving 465,000 shares worth $15.8M. The position accounts for 1.64% of the portfolio, ranked #14.

Ardsley Advisory Partners first reported a position in TEVA in Q4 2015 and has held it in 12 quarters since. The position peaked at $18.1M in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Ardsley Advisory Partners held 465,000 shares of Teva Pharmaceuticals worth $15.8M as of Q2 2026.
Ardsley Advisory Partners sold 90,000 Teva Pharmaceuticals shares in Q2 2026, an estimated $3M.
Teva Pharmaceuticals made up 1.64% of Ardsley Advisory Partners's portfolio in Q2 2026, its #14 holding.
Ardsley Advisory Partners first reported a position in Teva Pharmaceuticals in Q4 2015 and has held it in 12 quarters since.
Ardsley Advisory Partners's Teva Pharmaceuticals position peaked at $18.1M in Q4 2025.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Ardsley Advisory Partners's 13F filing for Q2 2026, filed 13 Jul 2026.